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Abstract
Background: Many countries have introduced legislations for public smoking bans to reduce the harmful effects of
exposure to tobacco smoke. Smoking bans cause significant reductions in admissions for acute coronary syndromes but
their impact on respiratory diseases is unclear. In Geneva, Switzerland, two popular votes led to a stepwise implementation
of a state smoking ban in public places, with a temporary suspension. This study evaluated the effect of this smoking ban on
hospitalisations for acute respiratory and cardiovascular diseases.
Methods: This before and after intervention study was conducted at the University Hospitals of Geneva, Switzerland, across
4 periods with different smoking legislations. It included 5,345 patients with a first hospitalisation for acute coronary
syndrome, ischemic stroke, acute exacerbation of chronic obstructive pulmonary disease, pneumonia and acute asthma.
The main outcomes were the incidence rate ratios (IRR) of admissions for each diagnosis after the final ban compared to the
pre-ban period and adjusted for age, gender, season, influenza epidemic and secular trend.
Results: Hospitalisations for acute exacerbation of chronic obstructive pulmonary disease significantly decreased over the 4
periods and were lowest after the final ban (IRR = 0.54 [95%CI: 0.42–0.68]). We observed a trend in reduced admissions for
acute coronary syndromes (IRR = 0.90 [95%CI: 0.80–1.00]). Admissions for ischemic stroke, asthma and pneumonia did not
significantly change.
Conclusions: A legislative smoking ban was followed by a strong decrease in hospitalisations for acute exacerbation of
chronic obstructive pulmonary disease and a trend for reduced admissions for acute coronary syndrome. Smoking bans are
likely to be very beneficial for patients with chronic obstructive pulmonary disease.
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Introduction
There is strong evidence that passive exposure to tobacco smoke
is harmful to human health [1]. Tobacco smoke has pro-
atherogenic and pro-thrombotic effects through various mecha-
nisms [2]. A systematic review of 18 cohort and case-control
studies demonstrated that exposure of non-smokers to second-
hand smoke (SHS) is associated with a 25% increased risk of
coronary artery disease and myocardial infarction [3]. Many
studies and meta-analysis showed a moderate, consistent and dose-
dependent association between exposure to SHS and the risk of
stroke, which is increased by 25%, suggesting a causal relationship
[4–6]. A strong and consistent association was reported between
SHS exposure and several respiratory hazards: respiratory
symptoms, worsening of lung function tests, prevalence of chronic
obstructive pulmonary disease (COPD) and asthma, risk of COPD
or asthma exacerbations and risk of hospital admission for COPD,
asthma or pneumonia [7–9].
Exposure to SHS causes an important health and economic
burden and is a major concern for health policy. Many countries
have therefore introduced legislation for smoking bans in public
and work places to reduce exposure to tobacco smoke. Numerous
studies and 2 meta-analyses have shown that legislation for
comprehensive smoking bans are associated with an average 15%
reduction of hospital admissions for acute myocardial infarction
and coronary events within a year [10–15]. Fewer studies and a
recent meta-analysis showed that a comprehensive smoke-free
legislation is followed by a 19% decrease in hospitalisations for
ischemic stroke [10,14–16].
Workplace smoking bans are associated with an improvement of
self-reported respiratory symptoms and lung function tests among
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hospitality employees heavily exposed to SHS [17–19]. Hospital
admissions for acute respiratory diseases were globally reduced by
24% after implementation of comprehensive smoke-free laws
[10,14–16]. The evidence is stronger for asthma among adults and
children with a decrease in emergency visits and hospitalisations
[8,10,14–16,20]. Two studies suggest a significant reduction of
admissions for pneumonia and a controversial effect on COPD
exacerbations, which does not emerge as significant in the meta-
analysis [10,14,16].
A legislative smoking ban in public places was implemented
after a popular vote on 1 July 2008 in the Canton of Geneva,
Switzerland. Three months later, the smoke-free law was cancelled
by the Supreme Court, which considered the implementing
regulation as unlawful. However many public places remained
smoke-free as managers maintained the ban voluntarily. A second
vote led to a permanent smoking ban, which was applied from 30
October 2009 [21].
The Department of Health of the Canton of Geneva called for
and sponsored this study to evaluate the effect of the public
smoking ban on hospital admissions for acute respiratory and
cardiovascular diseases at the University Hospitals of Geneva.
Materials and Methods
Ethics statement
The Ethics committee of the University Hospitals of Geneva
approved the study (protocol 10-241R) on 18 February 2011 and
waived the informed consent as only aggregate data from an
existing database were used.
Design and setting
We conducted this before and after intervention study in the
University Hospitals of Geneva, Switzerland, a 1900-bed univer-
sity and single public hospital in the Canton of Geneva, which is
populated by about 450,000 inhabitants. We collected data in four
periods defined according to the legislation on a public smoking
ban in the Canton of Geneva (Figure 1): the 2-year period before
the first smoking ban implemented on 1 July 2008 (Period 1); the
3-month period during the first smoking ban until its suspension by
the Supreme Court on 30 September 2008 (Period 2); the 13-
month period of suspended smoking ban from 1 October 2008
until the implementation of the final smoking ban on 31 October
2009 (Period 3); and the initial 14-month period of the final
smoking ban from 30 October 2009 to 31 December 2010 (Period
4).
Participants and data collection
From the hospital database of the University Hospitals of
Geneva, we extracted data on patients aged 16 and over admitted
between 1 July 2006 (104 weeks before the first legislation) and 31
December 2010 (61 weeks after the second legislation) with 5
primary diagnoses identified by the codes of the International
Classification of Diseases (ICD-10), 10th Revision [22]: acute
coronary syndrome (ICD-10 codes: I 21); cerebrovascular diseases
including ischemic stroke and transient ischemic attack (ICD-10
codes: I 63–67, G 45–46); COPD entities among chronic lower
respiratory diseases (ICD-10 codes: J 40–44); pneumonia or
influenza (ICD-10 codes: J 10–16), and asthma (ICD-10 codes: J
45-46). Like similar studies, we recorded only patients’ first
hospital stay [12]. Extracted information included date of
admission, gender, age, place of residence (Canton of Geneva,
other or unknown), and diagnosis at admission.
Because the definition of transient ischemic attack changed in
2009 [23], transient ischemic attack and ischemic stroke diagnoses
were combined into a single category (i.e. ischemic cerebrovascu-
lar accident). As a quarter of patients included in the study had
their residence outside of the Canton of Geneva, which could
mitigate the impact of smoke-free legislations in Geneva, we also
analysed data restricted to residents of the Canton of Geneva.
Statistical analyses
The means and frequencies with standard deviation and 95%
confidence intervals (95%CI) of study variables were computed.
The mean number of weekly admissions for each diagnosis was
calculated from the number of diagnosis-specific hospitalisations in
each study period. We used Poisson regression models to compute
the 95% CIs around these estimates and to test the hypothesis that
there was a change in the mean number of weekly admissions for
each diagnosis between the study periods corresponding to
changes in smoking ban legislation. Dummy variables for the
periods were created and the impact of smoking ban legislation
was estimated by incidence rate ratios (IRR) of diagnosis-specific
hospitalizations for the different periods, considering period 1 as
the reference period. Some of the disease-specific hospital
admissions, such as acute coronary syndrome, acute exacerbation
of COPD, and pneumonia, are known to vary with seasons or to
increase during the influenza epidemic [24]. Therefore, regression
models were adjusted for season (defined by calendar months) and
influenza epidemic periods using surveillance data of the Swiss
Office of Public Health [25–28]. To account for the potential
secular trends of diseases that would be independent of the
legislation periods, we included a linear time trend in the models.
Models were additionally adjusted for age and gender. The
seasonal effect and secular trends were taken into account with
methods previously used to allow comparison to previous large
population-based studies that measured the impact of smoking
bans on health outcomes [12,15,16,20]. We also examined
whether the slope of the trend change across periods, by adding
an interaction term between the study periods and the linear
predictor for time to the models and using likelihood ratio tests
[12]. For each outcome, we performed a global trend test of
adjusted incidence rate ratio across four periods, using period 1
(weeks 26 to 130) as the reference period, with its result expressed
as a global p-value.
To estimate the events prevented, the admission rates obtained
among Geneva residents were applied to the counts of population
aged over 15, using census data of Geneva for each study period
[29]. Hospital days and costs prevented by the smoking ban were
estimated using the University Hospitals of Geneva administrative
data.
All statistical analyses were performed using Stata 11.0 (Stata
Corp, College Station, USA).
Results
Patients’ characteristics
Overall, 5345 patients with a first hospitalization for acute
coronary syndrome, ischemic stroke, acute COPD exacerbation,
pneumonia and acute asthma were included (Table 1). Patients
were predominantly males, had a mean age of 67 years, stayed on
average for 11 days in hospital, and three-quarters of them lived in
Geneva. Admissions for acute cardiovascular events were more
numerous than for acute respiratory diseases. The socio-demo-
graphic profile and admission diagnoses were similar across the 4
study periods and for the sub-sample of Geneva residents.
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Effects of public smoking ban on hospital admissions
The mean number of weekly hospital admissions for all studied
conditions differed across periods for all population groups
(Table 2). The number of hospitalisations for pneumonia and
asthma was particularly low in each study period.
For acute COPD exacerbation, the weekly number of
hospitalisations significantly dropped over the 4 periods from
Figure 1. Adjusted weekly numbers of hospitalizations for acute COPD exacerbations and acute coronary syndromes (ACS).
Footnote: Global P values for adjusted incidence rate ratio trend tests (reference=period 1, weeks 26 to 130), see Table 2. Curves displayed using
smoothed values (Stata lowess function).
doi:10.1371/journal.pone.0090417.g001
Table 1. Socio-demographic characteristics and diagnoses for hospitalizations for all subjects and Geneva residents.
Total
Period 1: Before any
smoking ban
Period 2: Transient
smoking ban
Period 3: Suspended,
partial smoking ban
Period 4: Final
smoking ban
Geneva
residents
Number of patients 5345 2411 294 1271 1369 4034
Study period duration,
(weeks)
234.4 104.3 13 56.3 60.9 234.4
Gender, N (%)
Men 3226 (60.4) 1452 (60.2) 168 (57.1) 764 (60.1) 842 (61.5) 2393 (59.3)
Women 2119 (39.6) 959 (39.8) 126 (42.9) 507 (39.9) 527 (38.5) 1641 (40.7)
Mean age, years (IC 95%) 67.1 (66.7–
67.5)
67.6 (67.0–68.2) 66.5 (64.7–68.4) 66.6 (65.8–67.5) 66.7 (65.8–67.5) 68.5 (68.0–69.0)
Place of residence, N (%)
Canton of Geneva 4034 (75.4) 1806 (74.9) 199 (67.7) 966 (76.0) 1063 (77.6) 4034
Other 1002 (18.7) 461 (19.1) 70 (23.8) 229 (18.0) 242 (17.7) NA
Unknown 312 (5.8) 144 (6.0) 25 (8.5) 76 (6.0) 67 (4.9) NA
Mean hospital stay, days (IC
95%)
11.1 (10.8–
11.3)
11.1 (10.7–11.4) 11.9 (10.7–13.2) 10.8 (10.3–11.3) 11.1 (10.6–11.7) 11.4 (11.1–11.7)
Main diagnosis at admission,
N (%)
Acute coronary syndrome 1973 (36.9) 893 (37.0) 122 (41.5) 484 (38.1) 474 (34.6) 1431 (35.5)
Ischemic cerebrovascular
accident
2493 (46.6) 1079 (44.7) 135 (45.9) 610 (48.0) 669 (48.9) 1868 (46.3)
Acute COPD exacerbation 436 (8.2) 253 (10.5) 15 (5.1) 73 (5.7) 95 (6.9) 379 (9.4)
Pneumonia 239 (4.5) 105 (4.4) 9 (3.1) 52 (4.1) 73 (5.3) 195 (4.8)
Acute asthma 204 (3.8) 81 (3.4) 13 (4.4) 52 (4.1) 58 (4.2) 161 (4.0)
NA = not applicable.
doi:10.1371/journal.pone.0090417.t001
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2.45 to 1.54 (p,0.0001) (Table 2). The adjusted IRR decreased
significantly in all periods after the initial smoking ban; it reached
0.54 [95%CI: 0.42–0.68] for all patients and 0.53 [95%CI: 0.41–
0.68] for Geneva residents during the final smoking ban (period 4).
There was evidence of a change in the slope of the trend line
across the study periods (P = 0.001 for periods x secular trends
interaction). The reduction started before the legislative smoking
ban and became stable in the second part of the period 3, when
the ban was legislatively suspended but partially maintained in
practice (Figure 1).
Hospitalizations for acute coronary syndrome decreased only
during the final smoking ban (period 4), where we measured a
trend close to significance: adjusted IRR was 0.90 [95%CI: 0.80–
1.00] for all patients and 0.89 [95%CI: 0.78–1.02] for Geneva
residents (Table 2). The slope of the trend line did not change
across the periods (P.0.05 for periods x secular trends
interaction). The reduction started after the first legislative
smoking ban was suspended but partially maintained (period 3)
(Figure 1).
Despite variations in the number of admissions, adjusted
IRR of hospitalisations for pneumonia, acute asthma and
ischemic stroke, did not significantly change throughout the 4
periods.
Discussion
This study shows that a legislative smoking ban is associated
with a strong, highly significant reduction in hospitalisations for
COPD exacerbation and a trend for decreased admissions for
acute coronary syndrome. We observed no significant change in
admissions for pneumonia, acute asthma and ischemic stroke.
Strengths and limitations
Among the strengths of this study is the large sample covering
the large majority of hospital admissions in the community. It
investigated the impact of a smoking ban on several types of acute
respiratory and cardiovascular events, including some that were
less explored. In addition, it used a robust Poisson regression
analysis to better assess the specific effect of the smoking ban and
minimize confounding effects, particularly secular trends and
interaction with influenza epidemics.
The use of data from a single hospital is a study limitation but
the findings are probably generalizable for the Canton of Geneva.
Indeed, hospitalisations for acute events in the Canton of Geneva
are mainly centralized to the single acute care hospital of the
University Hospitals of Geneva, which is the only public hospital
of the Canton. For example, more than 90% of patients with an
acute coronary syndrome are admitted in this institution. As we
analysed retrospectively administrative hospital data, inaccurate
Table 2. Impact of smoking ban on hospitalizations for acute respiratory and cardiovascular diseases for all patients and Geneva
residents only.
Period 1: Before any
smoking ban
Period 2: Transient
smoking ban
Period 3: Suspended, partial
smoking ban
Period 4: Final
smoking ban
Global P
value
Number of weekly hospital admissions
Acute COPD exacerbation: All patients 2.45 (2.24–2.59) 1.12 (0.84–1.54) 1.33 (1.12–1.47) 1.54 (1.40–1.75) ,0.0001
Acute COPD exacerbation: Geneva
residents only
2.17 (1.96–2.31) 0.77 (0.49–1.19) 1.12 (0.98–1.33) 1.33 (1.19–1.54) ,0.0001
Pneumonia: All patients 0.98 (0.91–1.12) 0.70 (0.49–0.98) 0.91 (0.77–1.05) 1.19 (1.05–1.33)* ,0.0001
Pneumonia: Geneva residents only 0.91 (0.77–0.98) 0.35 (0.21–0.70) 0.70 (0.63–0.91) 0.98 (0.84–1.12) ,0.0001
Acute asthma: All patients 0.77 (0.70–0.84) 0.98 (0.77–1.33) 0.91 (0.77–1.05) 0.98 (0.84–1.12) ,0.0001
Acute asthma: Geneva residents only 0.56 (0.49–0.70) 0.70 (0.42–1.05) 0.77 (0.70–0.98) 0.77 (0.70–0.98)* ,0.0001
Acute coronary syndrome: All patients 8.54 (8.26–8.89) 9.38 (8.47–10.36) 8.61 (8.19–9.03) 7.77 (7.42–8.19) ,0.0001
Acute coronary syndrome: Geneva
residents only
6.16 (5.88–6.51) 6.79 (5.88–7.77) 6.23 (5.81–6.65) 3.28 (5.39–6.16) ,0.0001
Ischemic stroke: All patients 10.36 (10.01–10.71) 10.36 (9.45–11.41) 10.85 (10.36–11.34) 10.99 (10.57–11.48) ,0.0001
Ischemic stroke: Geneva residents only 7.56 (7.28–7.91) 6.72 (5.81–7.70) 8.83 (7.84–8.82) 8.61 (8.12–9.03) ,0.0001
Adjusted incidence rate ratios**
Acute COPD exacerbation: All patients ref 0.42 (0.25–0.71)* 0.42 (0.33–0.54)* 0.54 (0.42–0.68)* ,0.0001
Acute COPD exacerbation: Geneva
residents only
ref 0.36 (0.19–0.68)* 0.42 (0.32–0.55)* 0.53 (0.41–0.68)* ,0.0001
Pneumonia: All patients ref 0.58 (0.30–1.15) 0.74 (0.54–1.02) 1.00 (0.75–1.35) 0.12
Pneumonia: Geneva residents only ref 0.43 (0.18–1.06) 0.71 (0.49–1.01) 0.97 (0.70–1.35) 0.08
Acute asthma: All patients ref 1.10 (0.61–1.97) 1.14 (0.81–1.60) 1.17 (0.82–1.66) 0.81
Acute asthma: Geneva residents only ref 1.06 (0.53–2.15) 1.28 (0.87–1.87) 1.36 (0.91–2.01) 0.42
Acute coronary syndrome: All patients ref 1.06 (0.88–1.29) 0.98 (0.88–1.09) 0.90 (0.80–1.00) 0.24
Acute coronary syndrome: Geneva
residents only
ref 1.18 (0.95–1.48) 0.98 (0.86–1.12) 0.89 (0.78–1.02) 0.11
Ischemic stroke: All patients ref 0.92 (0.77–1.11) 0.95 (0.86–1.04) 0.98 (0.89–1.08) 0.64
Ischemic stroke: Geneva residents only ref 0.89 (0.71–1.11) 0.96 (0.86–1.07) 0.99 (0.89–1.11) 0.67
* P,0.05 compared to period 1; ** adjusted for age, gender, season, influenza epidemic and secular trend; ref = reference period.
doi:10.1371/journal.pone.0090417.t002
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coding of ICD-10 diagnoses at admission is possible and could
potentially lead to misclassification bias. This might particularly
affect patients admitted for combined acute COPD exacerbation
and pneumonia, leading eventually to overestimate the decrease in
admissions for COPD exacerbations. The hospital database only
includes data on patients who were admitted to a ward and
therefore patients who had ambulatory treatment were not
considered. This latter limitation particularly affects data on
patients admitted for acute asthma and pneumonia, who are
mainly managed as outpatients. Moreover, as we do not have
individual data on tobacco use and exposure to SHS, we were
unable to determine if the observed decrease in COPD
exacerbations was due to a decrease in cigarette consumption
among active smokers or to a reduction in exposure to SHS, or
both. Finally we did not conduct further stratified analyses (e.g. by
age group) because of the limited number of events.
Effects of public smoking ban on hospital admissions for
acute respiratory diseases
This study is the first to show such a large decrease in
admissions for acute COPD exacerbation after implementation of
a smoking ban in public places. Although it was little explored, this
effect was larger than expected, quickly detectable and progressive.
A COPD exacerbation is a complex event involving bacterial or
viral infections, constitutional factors, active smoking, exposure to
SHS and other environmental pollutants, which synergistically
induce a flare of inflammation in the lower airways [30]. The
observed decrease in hospital admissions may have been due to
reduced exposure to SHS and/or a decrease in active smoking
induced by the ban [11] but the distinction was not possible in our
study. In a Californian cohort, the risk of emergency department
visit was 40% higher among COPD patients exposed to SHS than
in non-exposed patients [31]. Exposure to SHS was an indepen-
dent risk factor for readmission in a cohort of Spanish patients
recruited during a hospitalization for COPD exacerbation [7].
The 46% reduction of admissions observed in our study was larger
than the 27% decrease reported after a comprehensive stepwise
smoking ban in Toronto [14] and the absence of change after
implementation of the work place smoking ban in Ireland [16].
These differences might be partly explained by the different
methods of adjustment between studies: the Canadian study
adjusted only for secular trend while the Irish study also used a
Poisson regression but adjusted for the seasonal temperature, levels
of particulate matter PM 2.5 and PM 10 and the intensity of
influenza epidemics. Finally, a secular trend is unlikely to explain
this decrease as the number of hospitalisations for COPD in
Switzerland declined by 27% from 2000 to 2006, but stabilized
thereafter. In our study, the reduction in hospitalisations was
larger (46%) and occurred later (2006–2010) [32].
Admissions for COPD exacerbations decreased progressively
before the first smoking ban. This effect can be explained by the
progressive introduction of smoke-free work and public places,
from 2003, before our first 2-year study period preceding the first
legislative smoking ban. Since 2003, the local tobacco control
association has offered support to companies, public services and
associations to implement smoke-free workplaces. Most of this
activity took place before study period 1, between October 2003
and June 2006 and reached 93 groups and more than 659000
persons. The activity decreased during the study period 1, when it
reached 35 groups and about 6500 persons (Unpublished data).
To estimate the public health impact from our results, the
smoking ban could prevent yearly 47 new hospitalisations for acute
COPD exacerbations, 680 hospital days and costs of CHF 1.28
millions (US$ 1.38 millions). As COPD exacerbations are
associated with deterioration of lung function, increased mortality
and decreased quality of life, a smoking ban has the potential to
bring considerable gains both for patients’ health and the public
health system, with a magnitude similar to therapeutic interven-
tions.
We did not find a significant reduction in hospitalisations for
asthma or pneumonia, as reported in other studies [8–
10,14,16,20]. Instead, we observed a slight, progressive but non-
significant trend towards an increase in admissions for acute
asthma throughout the periods. Although there is no clear
interpretation for this finding, it may be partly explained by the
very few cases of admissions for acute asthma and pneumonia
during the short summertime period corresponding to the initial
smoking ban. The 2009 influenza pandemic had its major impact
at a time that overlaps the end of the suspended ban and the
beginning of the final smoking ban. As we used the same
adjustment for influenza pandemic and seasonal epidemics, the
impact of the influenza pandemic on admissions for acute asthma
and pneumonia was probably underestimated in our model. There
is evidence showing that a third of patients hospitalized during the
2009 influenza pandemic had underlying respiratory disease and
that admission rates of patients aged under 65 were 6 times higher
than during seasonal epidemics [33,34]. Finally, as we did not
include patients with ambulatory treatment of pneumonia and
acute asthma, our sample was possibly too small to detect an effect
of the smoking ban on these outcomes.
Effects of public smoking ban on hospital admissions for
acute cardiovascular diseases
This study shows that the smoking ban was followed by a trend
towards a 10% decrease in hospitalisations for acute coronary
syndrome. Although the effect is not significant and lower than in
the largest meta-analysis (215%), it is within the range of previous
results [10]. For example, an English study observed an even
smaller reduction of admissions for myocardial infarction (22.4%),
which was significant in a very large national sample [12]. Like in
England, this lower effect can be due to the progressive reduction
of exposure to SHS because of stepwise implementation of
smoking restrictions before the first legislative smoking ban, as
described above. It is likely that a longer study with a larger sample
would show a significant reduction in hospitalizations for acute
coronary syndrome in Geneva. A seasonal fluctuation might cause
the moderate and non-significant reduction of incidence of acute
coronary syndrome. This is however unlikely as the incidence
would be expected to increase in autumn and winter after the
implementation of the final ban [35].
We did not find any association between the smoking ban and
admissions for ischemic stroke. However our finding is within the
same range as other individual studies, which did not report a
significant effect [10,14,16]. As there is evidence of an impact of
smoke-free legislation on ischemic stroke but not on transient
ischemic attack, a hypothetical effect may have been masked by
the combination of these diagnoses into the same category of
stroke.
Conclusions
The implementation of a legislative smoking ban is associated
with a strong reduction in hospitalisations for acute exacerbations
of COPD. This effect is even greater than the known reduction of
admissions for acute coronary syndrome. If confirmed in other
research, legislative smoking bans are likely to be beneficial for
both individual patients and as well as for the health care system as
it may be a very effective intervention to reduce COPD morbidity.
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